OnCusp Therapeutics

About OnCusp Therapeutics

OnCusp Therapeutics is a global biopharmaceutical company specializing in oncology, which is the study and treatment of cancer. The company focuses on transforming promising research into effective cancer treatments. Led by a team with extensive experience in business development and clinical research, OnCusp aims to accelerate the development of new cancer drugs to provide hope and help to patients worldwide.

The company operates in the biopharmaceutical market, targeting advanced solid tumors, which are masses of tissue that can be cancerous. OnCusp's primary clients are healthcare providers and institutions involved in cancer treatment, as well as patients who suffer from advanced stages of cancer.

OnCusp's business model revolves around developing a portfolio of first-in-class oncology assets. This means they focus on creating new and unique cancer treatments that have not been available before. They make money by advancing these treatments through various stages of clinical trials and then partnering with larger pharmaceutical companies for further development, commercialization, and distribution. These partnerships often involve licensing deals, where OnCusp receives upfront payments, milestone payments as the drug progresses through development stages, and royalties on sales once the drug is marketed.

One of their leading projects is CUSP06, a drug designed to treat advanced solid tumors that express a protein called Cadherin 6 (CDH6). CUSP06 is engineered to be more potent, stable, and effective against drug resistance, making it a potentially safer and more effective option for patients. The drug has shown promising results in preclinical trials and has recently entered Phase 1 clinical trials, which is the first stage of testing in humans.

In summary, OnCusp Therapeutics is dedicated to accelerating cancer drug innovation, leveraging its experienced team and strategic partnerships to bring new treatments to market.